[ad_1]
- Eliem Therapeutics (NASDAQ:ELYM) has introduced the appointments of Brett Kaplan as COO and Nishi Rampal as Senior Vice President, Clinical Development.
- Most not too long ago, Kaplan served as President and Chief Financial and Corporate Development Officer at Chroma Medicine Inc., the place he raised roughly $250 million to fund the analysis and improvement of epigenetic editors, a brand new class of genomic medicines.
- Most not too long ago, Rampal served as the Executive Director of Clinical Development at Horizon Therapeutics (acquired by Amgen, Inc. for $27.8 billion in October 2023), the place she was the worldwide lead on the event and technique for UPLINZA.
More on Eliem Therapeutics
[ad_2]
Source: Seekingalpha